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REVIEW
Physical activity and training in sarcoidosis: review and experience-based
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and Marjolein Drentb,c,g
aDepartment of Physical Therapy Hospital Gelderse Vallei, ZGV, Ede, Netherlands; bILD care foundation research team, Ede, Netherlands; cILD
Center of Excellence, St. Antonius Hospital Nieuwegein, Nieuwegein, Netherlands; dNew Orleans Scleroderma and Sarcoidosis Patient Care and
Research Center, Tulane University Lung Center, New Orleans, LA, USA; eDepartment of Rehabilitation, Nutrition and Sport, Alfred Health and La
Trobe University Clinical School, Melbourne, Australia; fDepartment of Medical Psychology, Elisabeth TweeSteden Ziekenhuis Tilburg and
Department of Medical and Clinical Psychology, CoRPS, Tilburg University, Tilburg, Netherlands; gDepartment of Pharmacology and Toxicology,
Faculty of Health, Medicine and Life Science, Maastricht University, Maastricht, Netherlands
ABSTRACT
Introduction: Sarcoidosis is a multisystemic inflammatory disorder with a great variety of symptoms,
including fatigue, dyspnea, pain, reduced exercise tolerance and muscle strength. Physical training has
the potential to improve exercise capacity and muscle strength, and reduce fatigue. The aim of this
review and survey was to present information about the role of physical training in sarcoidosis and offer
practical guidelines.
Areas covered: A systematic literature review guided an international consensus effort among sarcoi-
dosis experts to establish practice-basic recommendations for the implementation of exercise as
treatment for patients with various manifestations of sarcoidosis. International sarcoidosis experts
suggested considering physical training in symptomatic patients with sarcoidosis.
Expert commentary: There is promising evidence of a positive effect of physical training.
Recommendations were based on available data and expert consensus. However, the heterogeneity
of these patients will require modification and program adjustment of the standard rehabilitation
format for e.g. COPD or interstitial lung diseases. An optimal training program (types of exercise,
intensities, frequency, duration) still needs to be defined to optimize training adjustments, especially
reduction of fatigue. Further randomized controlled trials are needed to consolidate these findings and
optimize the comprehensive care of sarcoidosis patients.
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Physical training or pulmonary rehabilitation (PR) is an impor-
tant element of the comprehensive care of people with pul-
monary diseases and other chronic diseases, including
musculoskeletal disorders, neurological diseases, and psychia-
tric conditions [1–6]. Of note, exercise also has a role as treat-
ment in diseases such as those of the locomotive apparatus or
respiratory system that do not primarily manifest as organ-
specific disorders, but also are accompanied by many other
clinical manifestations such as fatigue and other disabling
nonspecific symptoms [3,6]. In selected cases, exercise therapy
might be just as effective as medical treatment, and in special
situations it might be more effective or add to its effect [6].
Sarcoidosis, a multisystem inflammatory disorder, has many
faces and phenotypes. It may occur at all ages and presents with
lung involvement in the majority of cases [7–11]. Extrapulmonary
manifestations of this disease involve the heart, joints, kidney, liver,
eyes, nervous system, and skin. A growing body of evidence has
demonstrated the impact of not only organ-specific symptomsbut
also nonspecific problems, including lack of energy, fatigue, pain,
anxiety, depression, and cognitive symptoms, on patients’ lives,
inducing significantworseningof (health-related) quality of life (HR
QoL) [10,12–14]. Multifactorial influences include systemic inflam-
mation, decreased pulmonary function, sleeping disorders, small
fiber neuropathy (SFN), sarcoid myopathy, hypoxia or glucocorti-
coid use, and deconditioning [15–18]. This can lead to physical
inactivity, loss of fitness and muscle strength, and thus increased
fatigue [19,20]. Considerable knowledge has accumulated con-
cerning the significance of exercise as the first-line treatment of
several chronic diseases [6]. To date, no formal consensus exists
regarding the role of exercise programs for sarcoidosis.
To collect information about the benefits of physical train-
ing in sarcoidosis, a comprehensive literature review was per-
formed, which was then used to guide an international
consensus effort among sarcoidosis experts to establish prac-
tical recommendations – based on evidence, experience, and
common sense – for the use of physical training in the man-
agement of patients with manifestations of sarcoidosis.
CONTACT Marjolein Drent m.drent@antoniusziekenhuis.nl; Pulmonology and interstitial lung diseases (ILD), ILD Center of Excellence St. Antonius Hospital
Nieuwegein, PO Box 18, Bennekom 6720 AA, The Netherlands
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2. Material and methods
This study consisted of four phases.
2.1. Phase I
A computerized comprehensive search of the literature from
January 1971 until December 2015 was performed. Results
were identified in PubMed, MEDLINE, and CINAHL.
Combinations of the following Medical Subject Headings
(MeSH) and free text words were used: sarcoidosis, interstitial
lung disease, physical training, training, physical therapy, exer-
cise, exercise training, exercise capacity, outcome, evaluation.
The following criteria were used to identify relevant studies:
(1) patients: sarcoidosis, interstitial lung disease;
(2) intervention: physical training/exercise training/physical
therapy/PR; and
(3) language: English.
We augmented our search by reviewing the reference lists
of retrieved articles, including review articles. The initial selec-
tion was done by two authors (LAS and BS). Consensus regard-
ing ‘title and abstracts’ was reached by two authors (MD and
BS). Data was extracted by BS and checked by MD, see
Figure 1. A descriptive summary of studies included presents
the study design, participant and treatment characteristics, as
well as objective and patient-reported outcomes (see also
Table 1).
The study quality was assessed using appropriate instru-
ments, viz. the STROBE Statement [25] for observational stu-
dies and PEDro scale [26,27] for randomized trials.
2.2. Phase II
The results and conclusions from the literature review in Phase
I provided key concepts regarding PR and physical training in
interstitial lung disease (ILD) and in sarcoidosis. These con-
cepts reflect the scientific efforts and experienced opinion of
the expert community.
Thus, Phase II involved content analysis of the literature
review (LAS, BS), deconstructing the text of each paper into
individual topics and reassembling them into a nonredundant
and categorized item list. Each item from Phase II was directly
translated into a representative survey question, which together
formed the questionnaire used in Phase III of the study.
2.3. Phase III
Phase III comprised an evaluation of physical training in sar-
coidosis by international sarcoidosis experts. The active data
collection occurred during 6 weeks in August and September
2015; 165 international sarcoidosis experts were invited by
email to complete a web-based survey on physical training
in sarcoidosis. The experts selected were members of the
World Association of Sarcoidosis and Other Granulomatous
Disorders (WASOG) or the American Association of
Sarcoidosis and Other Granulomatous Disorders (AASOG), or
Potentially relevant studies 
identified: n= 170
Studies screened on title and 
abstract: n=99
Full text of studies retrieved for 
detailed evaluation: n=42
Studies included in review on physical 
training in sarcoidosis: n=4
Studies excluded after detailed evaluation: 
n=37; irrelevant: n=23; physical training in 
mixed ILD: n=6; physical training in IPF: n=8; 
duplicate patients: n=1
Studies excluded on title and abstract: n=57; 
irrelevant: n=47; physical training    in other 
patients: n=5; no intervention: n=5
Removal of duplicate and clearly irrelevant 
studies: n=71
Figure 1. Flow-chart of the literature review.















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































EXPERT REVIEW OF RESPIRATORY MEDICINE 1059
identified by authorship in peer-reviewed journals in related
studies. Additionally, the respondents were subdivided by
region: Europe, United States and Canada, and rest of the
world (including Russia, Asia, Australia).
2.4. Survey
The survey consisted of two parts. All participants were asked to
complete Part I of the survey, which collected sarcoidosis-specific
demographic data including specialty, degree of clinical experi-
ence, and perceptions and regional availability of physical training.
Part II of the survey included only participants self-defined
as being familiar with physical training in sarcoidosis. Items
were divided into two major areas: (1) potential sarcoidosis
manifestations (e.g. pulmonary, cardiac) and symptoms (e.g.
fatigue, dyspnea) as indications for physical training; and (2)
potential domains and tools to monitor the impact of physical
training (e.g. fatigue or dyspnea scales, lung function).
The survey items were rated on a 10-point Likert scale from
1 (not at all) to 10 (absolutely), anchored in either useful or
appropriate depending on the item content. This included the
degree of appropriateness of physical function testing (e.g.
exercise capacity, muscle function, activities of daily living) as
part of the standard assessment of any patient with sarcoido-
sis. Additionally, open-ended questions were posed, such as
those querying relative contraindications of physical training
in sarcoidosis. Finally, participants ranked the top three
domains for monitoring physical training in sarcoidosis.
2.5. Phase IV
In Phase IV, results obtained during Phases I and III were assembled
to prepare 10 recommendations (MD, LAS, BS). Finally, the recom-
mendations were submitted to a panel of 15 leading international
sarcoidosis experts familiar with exercise in sarcoidosis who each
sawover 100newsarcoidosis patients a year. The experts indicated
their level of agreement on a 10-point Likert scale from 1 (no
agreement) to 10 (full agreement) [28]. The experts were also
asked to comment on each recommendation. The specific com-
ments on the recommendations were gathered and grouped (by
BS and MD), and recommendations were refined on the basis of
these comments. Recommendations with an agreement level less
than 75% were excluded from the final selection.
2.6. Statistical analysis
Standard proportional analyses were performed on aggregate
responses. Chi-square analyses were used to assess regional differ-
ences. Descriptive statistics were used for the recommendations of
Phase IV. All statistical analyses were performed using SPSS statis-




A systematic literature review (Figure 1) yielded 42 studies on
PR or physical training in ILD. Twenty-three were irrelevant
after detailed evaluation, eight studied patients suffering from
idiopathic pulmonary fibrosis (IPF), six patients with mixed ILD
etiology, and one study analyzed patients also included in one
of the other included studies. Therefore, finally, only four
studies were included. Average observational study quality,
assessed by the STROBE checklist, was 25 out of 34 points
(range 20–30). The quality of the randomized trial, assessed by
the PEDro scale, was 9/11, see also Table 1.
Two of the four included studies were retrospective cohort
studies [21,23], one was a prospective cohort study [22], and
one was a randomized controlled trial [24]. Specific informa-
tion regarding patient characteristics for the sarcoidosis sub-
population in the study by Huppmann et al. could not be
determined from the paper or from personal correspondence
with the authors [21]. Information regarding the outcomes for
the sarcoidosis subpopulation was presented by the authors in
personal correspondence.
The age of the patients was similar across all other studies
(average 48 years), and the percentage of women in the
studies was also similar (ranging from 42% to 66%).
However, the study by Marcellis et al. had a smaller proportion
of women (22%) [22].
Chest radiographic stages showed some variance across the
study populations. All of the sarcoidosis patients in the study by
Karadalli et al. had chest X-ray stage I or II [24]. In the other two
studies, most patients had stage II or III (50–66%) [22,23].
The majority of patients were outpatients who performed
their specific training regimen two to three times a week
[22,23,29]. Patients in the study by Huppmann et al. trained
four to five times a week on an inpatient basis [21]. The
interventions consisted of endurance training, peripheral mus-
cle training [22,23,29] and inspiratory muscle training [24],
exercise training, breathing training, and education [21].
Each study suggested benefits in the areas of exercise
capacity, fatigue, and QoL [21–24].
In all of the studies, the exercise capacity (6-minute walking
distance, 6MWD) improved, ranging from 34 to 70 m improve-
ment. In the study of Marcellis et al. and Strookappe et al., fatigue
decreased significantly, −2.7 points (CI −4.4 to 1.1) and −4.2 (CI
−5.4 to −2.7) points on the Fatigue Assessment Scale (FAS),
respectively [22,23]. Huppmann et al. and Marcellis et al. found
improvement of health status [21,22]. Marcellis et al. also showed
improvement of quadriceps femoris muscle strength (+10.7 kg;
CI 5.5 to 15.9) [22]. In the RCT of Karadalli et al., patients who
performed the inspiratory muscle training program improved
their inspiratory strength significantly compared with the con-
trols (PImax +45.9 cmH2O, CI 39.3 to 52.8, p < 0.001) [24].
More information is provided in Table 1.
3.2. Phase II
Content analysis of the literature review resulted in 28 draft
recommendations, 10 of which were related to specified
symptoms or organ manifestations that justified indications
for physical training, 15 to clinical end points in physical
training, and three to general assessment in sarcoidosis.
These were further deconstructed and translated into discrete
survey items with 28 questions and 15 suggestions for rating
and priority ranking.
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3.3. Phase III
In Phase III of the study, 165 of the world’s leading sarcoidosis
experts of varying specialties were consulted with a web-
based survey, of whom 108 (65%) participated. The great
majority of the participants were pulmonologists (82%).
Other specialists and health-care workers included: rheumatol-
ogists (7%), internists (4%), cardiologists (3%), neurologists
(2%), and other specialists (all <1%, including immunologists,
physical therapists, and oncologists). More than half (55%) had
more than 15 years’ experience with sarcoidosis (70%
>10 years). Of the overall patient populations seen by the
participants, 61% had severe pulmonary sarcoidosis and 49%
had severe extrapulmonary sarcoidosis. Participant demo-
graphics are shown in Table 2.
The majority of participants rated physical training as valu-
able in sarcoidosis (81%, n = 87). Only 3% (n = 4) considered it
not valuable and 16% (n = 17) expressed being uncertain
about this. These latter respondents also indicated being
unfamiliar with physical training in sarcoidosis. The majority
of respondents (69%, n = 75) reported that their patients
generally had access to physical training. However, insurance
coverage of and access to physical training for sarcoidosis
were available only in some regions (see Table 3). Most
respondents (62%, n = 67) would refer patients ‘regularly,
often or always’ if physical training was available for sarcoido-
sis, with pulmonary involvement and fatigue being the most
prominent indications for referral (see Table 3).
Respondents familiar with physical training in sarcoidosis
(n = 60) also completed part II of the survey. In their assess-
ment of physical training, several domains were rated as
important (median Likert 1–10, range for all respondents):
QoL (9; range 2–10), exercise capacity (9; range 2–10), activity
level (9; range 3–10), fatigue (8.5; range 0–10), health status (8;
range 2–10), muscle strength (8; range 2–10), dyspnea (8;
range 0–10), and mental health (8; range 2–10). The highest
levels of agreement on indications for physical training were
pulmonary involvement, fatigue, and muscular and extrapul-
monary involvement (see Table 4). Sarcoidosis experts from
Europe reported a higher likelihood of physical training refer-
ral for extrapulmonary sarcoidosis than respondents from
other regions.
Half of the respondents considered physical training a safe
intervention in sarcoidosis without need for restrictions.
Almost 50% of respondents (29/60) indicated situations of
potential harm from physical training, e.g. for patients with
cardiac involvement (e.g. untreated arrhythmias (n = 17, 28%))
or sarcoidosis-associated pulmonary hypertension.
3.4. Phase IV
In Phase IV, results obtained during Phases I and III were
assembled to prepare 10 recommendations (MD, LAS, BS)
(see Section 2.5). The recommendations were reviewed by 15
leading international sarcoidosis experts familiar with exercise
in sarcoidosis. Recommendations with an agreement level less
than 75% were excluded from the final selection. This review
process led to the exclusion of two recommendations, result-
ing in the final eight recommendations.
The eight key remaining recommendations are presented
in Table 5 with their levels of agreement. The mean level of
agreement for the total set of these initial recommendations
among the 15 leading sarcoidologists was 7.8 ± 0.8.
4. Discussion
Physical activity brings health benefits [33,34]. However, the
best way to implement this awareness into the care of sarcoi-
dosis patients to reduce physical inactivity and fatigue has to
be explored. A comprehensive literature review was per-
formed regarding the role of physical training in sarcoidosis
patients, to guide an international consensus effort among
sarcoidosis experts to establish practical recommendations
for the use of physical training in the management of various
manifestations of sarcoidosis. Although relatively few studies
have been done so far, there is encouraging evidence of a
positive effect of physical training on the devastating symp-
toms of sarcoidosis. Despite the paucity of studies, available
data and scientific rationale induced a multinational commit-
tee of sarcoidosis experts to recommend that sarcoidosis
patients might benefit from supervised tailored physical train-
ing with serial assessment of muscle strength and exercise
capacity. Physical training was recognized as a strategy to
reduce fatigue and dyspnea, as well as to improve QoL.
4.1. Heterogeneity of sarcoidosis
Due to the heterogeneity of the disease and the diversity in
severity, sarcoidosis patients may present with a variety of organ-
Table 2. Demographics of respondents to the survey [30–32].
Europe n = 54 US and Canada n = 27 Other n = 27 Total population n = 108
Age, years
31–45/46–60/>60, % 26/54/20 41/37/22 55/30/15 36/45/19
Specialty
Pulmonologist, % 85 74 82 82
Experience, years
0–5/5–10/1015/15/25/>25, % 6/15/18/28/33 15/26/7/19/33 4/37/11/26/22 7/23/14/25/31
Percentage of patients with pulmonary sarcoidosis
Less severe (chest X-ray stage 0–I), % 37 ± 24 32 ± 25 47 ± 26 38 ± 25
Severe (chest X-ray stage II–IV), % 61 ± 25 68 ± 24 53 ± 26 61 ± 25
Percentage of patients with extrapulmonary sarcoidosis
Less severe, % 45 ± 26 41 ± 24 60 ± 31 48 ± 27
Severe, %* 54 ± 27 59 ± 23 30 ± 25 49 ± 28
*Severe: clinically relevant lesions for which treatment is recommended.
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related symptoms and functional impairments. Moreover, they are
often affected by rather nonspecific disabling symptoms. In addi-
tion to the impact of inflammation and treatment on muscles on
the one hand, there is a well-described relationship of reduced
physical activity/deconditioning, fatigue, and exercise intolerance
with peripheral muscle integrity, comparable to that in other
chronic diseases, and not only respiratory disorders, on the other
hand [3,6,23]. This underlines that the treatment should be






1 The cause of fatigue in sarcoidosis patients can be multifactorial. Therefore, other causes beside sarcoidosis-associated
fatigue should be excluded.
9.7 ± 0.6 2B
C
2 Standardized fatigue assessment (with a validated instrument, e.g. FAS) is recommended in the work-up of sarcoidosis
patients.
7.0 ± 2.4 2B
B
3 In the assessment of the severity and extent of the disease in symptomatic sarcoidosis patients with fatigue and/or exercise
limitation, evaluation of exercise capacity (submaximal or maximal exercise test, e.g. 6MWD, CPET) as well as muscle
strength assessment should be considered.
7.2 ± 2.4 2B
C
4 To achieve improvement of sarcoidosis-associated fatigue, a physical training program is recommended in symptomatic
sarcoidosis patients, complementary to the medical treatment.
7.7 ± 2.9 2B
C
5 Symptomatic sarcoidosis patients with fatigue and/or exercise limitation suffering from various manifestations might
benefit from a supervised physical training program, not only patients with pulmonary manifestations.
7.6 ± 3.1 2B
C
6 A correctly monitored supervised physical training program in sarcoidosis is safe and has no absolute contraindications
based on its acceptable safety profile. However, manifestations of pulmonary hypertension and cardiac involvement
should be considered as relative contraindications and caution should be exercised by the qualified supervisors.
7.7 ± 2.4 5
D
7 When starting physical training in symptomatic sarcoidosis, standardized evaluation of exercise capacity (e.g. 6MWD),
muscle strength, and fatigue (e.g. FAS) is recommended at baseline and after completion of the program.
7.5 ± 2.9 3B
C
8 Aerobic endurance training and peripheral muscle strengthening are both recommended in a supervised physical training
program for sarcoidosis patients.
7.6 ± 2.8 3B
C
LoE: Levels of Evidence; GoR: Grade of Recommendations
FAS: Fatigue Assessment Scale; 6MWD: six-minute walking distance; CPET: cardiopulmonary exercise test.
*The level of agreement was measured on a 10-point Likert scale (from 1, no agreement, to 10, full agreement).
**Level of Evidence and Grade of Recommendation according to Oxford Centre for Evidence-Based Medicine.









Are you familiar with physical training in sarcoidosis?
Yes/no, % 65/35 70/30 41/59 60/40
Do you consider physical training valuable in sarcoidosis?
Yes/no/not sufficiently familiar, % 89/4/7 78/0/22 67/4/30 81/3/16
Physical training is available in the region where I work for sarcoidosis patients.
Yes/no/not sufficiently familiar, % 72/20/8 67/26/7 56/33/11 67/25/8
If you do have access to physical training are you likely to refer sarcoidosis
patients?
Regularly/often/always, % 67 59 67 65
Never/occasionally, % 33 41 33 35
Physical training is reimbursed by health insurers for sarcoidosis patients in my
country.
Yes/sometimes/not sufficiently familiar, % 26/32/41 7/56/37 19/22/59 20/36/44
Regional restrictions have kept me from referring patients to physical training.
Yes/no/not sufficiently familiar, % 41/46/13 44/44/12 44/41/15 43/44/13
Table 4. Indications for physical training in sarcoidosis.
Do you perceive physical training to be beneficial in
sarcoidosis patients with: Europe n = 32 US and Canada n = 15 Other n = 13 Total population n = 60
Pulmonary involvement 8.2 ± 1.7 8.2 ± 1.2 7.9 ± 1.7 8.1 ± 1.6
Mild pulmonary involvement 6.7 ± 2.7 6.3 ± 3.0 6.7 ± 2.8 6.6 ± 2.7
No pulmonary involvement a 7.7 ± 1.9 6.8 ± 2.2 5.9 ± 2.9 7.1 ± 2.3
Fatigue 8.2 ± 1.7 7.5 ± 2.1 7.3 ± 2.8 7.8 ± 2.2
Small fiber neuropathy 6.4 ± 2.5 5.9 ± 2.7 6.8 ± 2.8 6.4 ± 2.6
Arthritis 6.2 ± 2.4 6.6 ± 2.4 5.3 ± 2.2 6.1 ± 2.4
Muscular involvement 7.3 ± 2.5 6.9 ± 2.6 7.0 ± 2.5 7.1 ± 2.5
Neurosarcoidosis 6.2 ± 2.4 5.7 ± 3.0 6.7 ± 2.4 6.2 ± 2.5
Cardiac involvement 5.7 ± 2.0 6.7 ± 2.9 5.6 ± 2.6 6.0 ± 2.4
Likert 0–10. Data are expressed as mean ± SD
p < 0.05: a Europe vs. Other.
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individualized and tailored to the personal needs and cover all
clinically relevant symptoms (see also Table 5). Due to its complex-
ity, sarcoidosis requires a multidisciplinary approach [10,35].
4.1.1. Fatigue and dyspnea
Fatigue is the most frequently described and disabling symptom
in sarcoidosis and can be nonspecific and difficult to characterize
for both patients and clinicians [20,36]. Sarcoidosis-associated
fatigue and exercise capacity have important associations with
QoL, especially in the domain of physical health [17,37–40]. Even
so, the fatigue associated with systemic inflammation is multi-
dimensional and can be subclassified as general, mental, physical,
or motivational fatigue. Inflammation-related fatigue exerts cyto-
kine/chemokine influences on the hypothalamus, muscle (includ-
ing respiratory muscles), nerve, and bone, leading to mental
exhaustion, sleep disorders, loss of muscle and bone mass and
autonomic dysfunction, as well as the exhausting psychological
burden of pain in addition to that of living with a chronic illness. In
patients with sarcoidosis, sarcoidosis-associated pulmonary hyper-
tension and sleep apnea are important disease aspects that are
potential causes of fatigue, which need to be excluded [20,41–43].
Fatigue can also be a consequence of the treatment itself, such as
corticosteroid therapy, which also affects the hypothalamic axis as
well as other endocrine functions and muscle health [7]. Like
fatigue, dyspnea is a significant symptom and multifactorial phe-
nomenon in sarcoidosis [41,44–49]. Dyspnea appears to be related
to fatigue, low levels of energy, and chest pain [22,46,49,50].
However, the degree of dyspnea in sarcoidosis does not correlate
with lung function tests [51].
In line with the studies done so far, practical recommenda-
tions (Table 5) show that fatigue was considered by the sar-
coidosis experts to be a key element in the management of
sarcoidosis patients. This makes assessment of fatigue an
important metric in addition to objective clinical and labora-
tory data. Accordingly, it was recommended by 15 leading
sarcoidologists that measurement of patient-reported fatigue
in combination with assessment of physical activity and func-
tional performance may offer useful clinical information in the
evaluation of fatigue in patients with sarcoidosis. Moreover, it
was recognized that – as the etiology of fatigue is elusive and
may be multifactorial – the diagnosis of sarcoidosis-associated
fatigue requires extensive evaluation to identify and treat
potentially reversible causes, including non-disease-related
causes such as hypothyroidism (Table 5) [7,20].
4.1.2. Muscle strength and deconditioning
Patients with sarcoidosis may experience respiratory as well as
limb muscle dysfunction, and the ensuing deconditioning,
inactivity, and exercise tolerance [3,5,11,19,23,52].
Wirnsberger et al. found reduced respiratory muscle strength
and endurance time in a small population of sarcoidosis
patients with normal lung function [53]. More recently, it was
demonstrated that not only fatigue but also exercise intoler-
ance and muscle weakness were frequently reported, with
substantial reduction of maximal inspiratory pressure (PImax)
[11]. Interestingly, maximal inspiratory and expiratory mouth
pressures in sarcoidosis patients demonstrated a more consis-
tent gradual decline with increasing dyspnea and diminishing
activity levels than lung volumes and gas transfer [54].
However, the assessment of muscle strength is variable in
clinical practice. The Biodex System 3 Pro Dynamometer
(Biodex Medical Systems, Shirley, New York, USA), which is
the gold standard in muscle strength testing, was used to
assess muscle function in sarcoidosis. However, this system is
quite expensive, not portable, and has limited availability in
clinical practice, which limits its practical usability. The
microFET (Biometrics, Almere, The Netherlands), used in the
study of Marcellis et al. and Strookappe et al., is a handheld
dynamometer and could offer a reliable alternative to measure
peripheral muscle strength [22,23,55].
Although asymptomatic muscle involvement in sarcoidosis
has been reported in up to 80% of cases, symptomatic involve-
ment is thought to be less frequent [7,56–59]. Symptomatic
muscle involvement may include palpable nodules, acute myo-
sitis, and chronic myopathy with or without functional impair-
ment [60]. According to the results reported in the literature,
respiratory as well as limb muscle dysfunction are also impor-
tant in considering when to start a physical training program.
These latter considerations were appreciated by the experts as
recommendation (Table 5). Whether impaired respiratory mus-
cle function impacts on morbidity and mortality, in sarcoidosis
as in other ILDs, needs to be further investigated [61].
4.1.3. Small fiber neuropathy
SFN has been recognized as a serious phenomenon in sarcoi-
dosis [62]. Symptoms affecting the autonomic nervous system
generally take the form of pain, constipation, incontinence,
and in some cases erectile dysfunction and orthostatic hypo-
tension. Patients also experience insomnia and depression at
an advanced stage of the disease, with some patients experi-
encing memory problems and a lack of concentration and
initiative [63]. There is a positive association between SFN-
associated symptoms and fatigue [17,64]. Moreover, SFN may
at least partly explain muscle dysfunction and exercise limita-
tions. Since symptoms of SFN are disabling for patients, they
can also significantly reduce their health status [64–66]. To
date, SFN itself is often difficult to treat [10,67].
4.1.4. Side effects of medical treatment
Medical treatment for sarcoidosis is often associated with bur-
densome side effects, with glucocorticoids being known to
cause myopathy [68], fatigue, psychological burden, and sleep-
ing problems [42,47,69]. In a study among 25 patients with
sarcoidosis, only in the patients who received oral corticosteroid
treatment (n = 11) was the quadriceps peak torque inversely
related to the mean daily dose of corticosteroids received in the
6 months before testing [18]. Thus, steroid myopathy may be a
clinically relevant entity in sarcoidosis, especially with intensified
corticosteroid treatment. However, two studies found that the
medication did not contribute much and does not impact on
the health status more than the symptoms of sarcoidosis [14,49].
Sarcoidosis-related muscle effects at the tissue, cellular, and
molecular levels require further investigation.
4.1.5. Quality of life
The majority of patients with sarcoidosis have impaired QoL
and health status due to the burden of the disease, leading to
limitations in activities of daily living, social isolation, and
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depression [10,13–15]. In line with others, Salligan demon-
strated in a small study that sarcoidosis patients were more
fatigued, more depressed, more dyspneic, and less physically
active, and had lower physical performance than their age-
and race-matched controls [70].
Sarcoidosis-related complaints, including fatigue, may
become chronic and affect patients’ QoL even after all other
signs of disease activity have disappeared; this appears to be
unique to sarcoidosis-related fatigue as compared to other
inflammatory conditions [36,71]. Physicians generally assess dis-
ease severity and progression in sarcoidosis on the basis of so-
called ‘objective measures’ such as pulmonary function tests,
chest radiographs, and serologic tests. However, these para-
meters correlate poorly with the patients’ subjective sense of
well-being. Marcellis et al. demonstrated that fatigue and QoL
were closely correlated over a 2-year follow-up period, suggest-
ing that reduced muscle strength and exercise intolerance
underlie fatigue in sarcoidosis [45]. Inspiratory muscle endur-
ance and quadriceps strength each correlated strongly with SF-
36 (medical outcomes study 36-item short form health survey)
scores, especially the physical subscales [72]. In recent years,
patient-related outcome measures (PROMs) have gained
increasing recognition in terms of their value in clinical trials to
quantify patient-perceived health status, which is now a stan-
dard outcome measure [13]. Moreover, patient involvement can
influence the priorities of clinical care. In the management of
sarcoidosis, therapeutic approaches should include strategies to
restore QoL, with special emphasis on energy and fatigue [9,38].
In terms of the impact on patients’ lives, lack of energy, physical
impairment, and fatigue are the most important QoL domains
affecting them. Therefore, in line with the results of earlier
studies, the experts agreed on recommending a physical train-
ing program in sarcoidosis patients suffering from substantial
symptoms, complementary to the medical treatment (Table 5).
4.2. Physical training in sarcoidosis
The literature review revealed that the evidence for the role of
physical training is limited but promising (Table 1) [21–24]. The
only three currently available observational non-randomized stu-
dies and one randomized controlled trial evaluating physical
training in sarcoidosis found significant and clinically relevant
benefits [21–24]. Two studies reported that a physical training
program improved exercise capacity and muscle strength and
reduced fatigue in sarcoidosis, and recommended that physical
training be included as a first-line therapy in sarcoidosis [22,23].
Both Marcellis et al. and Strookappe et al. found a significantly
greater decrease of fatigue in physical training groups compared
with the patients who did not complete a physical training
program. These findings show consistent observational relation-
ships between fatigue and reduced 6MWD, respiratory muscle
weakness, and reduced peripheral muscle strength, as well as
significant tandem improvement in sarcoidosis-associated fati-
gue, psychological health, and physical functioning after a period
of physical training [22,23]. Huppmann et al. described that an
inpatient PR program had a positive impact on the functional
status and HR QoL of patients with ILD, including sarcoidosis
patients (n = 50; 12%) [21]. In the original article, data on the
sarcoidosis patients was not presented separately [21].
Specifically, Karadalli et al. demonstrated that inspiratory muscle
training improves functional capacity, maximal exercise capacity,
and respiratory muscle strength, while reducing severe perceived
fatigue and dyspnea in the early stages of sarcoidosis, and could
be safely added to rehabilitation programs [24]. Early referral to
physical training should be considered, as less severe physiolo-
gical limitation may provide greater opportunity to successfully
undertake training [52]. But several studies found that patients
with very low functional exercise capacity and severe symptoms
should be offered the opportunity to undertake a training pro-
gram and may experience clinically important benefits [1,73].
In one of the studies excluded of final analysis (due to
duplicate patients with an included study) [29], patients
(n = 12) with severe respiratory involvement (stage IV fibrotic
sarcoidosis) were analyzed after a 12-week training program.
Exercise capacity and muscle strength were improved in half
of the patients. An increased 6MWD of >10% was found in
50% of the patients, and 58% of the patients improved their
hand grip strength by >10%. There was also a trend regarding
improvement of the forced vital capacity (FVC) % of predicted
(Δ = 9.7 ± 11.4; p = 0.075).
4.3. Survey
Eight recommendations for the practical use of physical training
in sarcoidosis were developed by integrating evidence from
both our systematic literature review and the experiential opi-
nions of sarcoidosis experts worldwide (Table 5). In the con-
sensus process, the knowledge and experience of 108
international sarcoidosis experts were harnessed to bridge the
gaps in the available evidence. The agreement by this large
expert group provides a valuable platform for the implementa-
tion and adjustment of these physical training recommenda-
tions for sarcoidosis. Such strength of consensus is anticipated
to increase the awareness and availability of physical training as
a safe and cost-effective strategy in the management of sarcoi-
dosis. The present study was also a first attempt to increase the
awareness that sarcoidosis patients might benefit from physical
training, like many other patients suffering from any kind of
chronic disease [6]. Further studies are urgently needed.
4.4. Effect of physical training
Physical activity increases aerobic capacity and muscle
strength, and thus physical well-being.
Rehabilitation has many benefits for patients with sarcoidosis,
including social participation, psychological well-being, maintain-
ing levels of activity, learning to use breathing exercises, and ways
to adapt exercises to the home environment [5,22,29,74]. In the
broader context of medical management, physical therapy or
rehabilitation can help to avoid a negative vicious circle of decon-
ditioning and improve coping with the disease [18,22].
4.5. Optimizing physical therapy
The duration, frequency, and intensity of exercise programs
are critical to achieve physical benefits [12,23,52]. Although
physical training interventions described for ILD show great
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similarities with interventions used in other chronic lung dis-
eases, e.g. COPD [2,75], lessons learned from other disorders,
like neurological and rheumatologic disorders, should be
taken into account as well [6]. Studies carried out so far
involving subjects with sarcoidosis have shown that physical
activity can reduce their symptoms. The positive effect of
physical training in sarcoidosis is believed to be multifactorial.
The physical training program in sarcoidosis must be indivi-
dualized and should focus on the patients’ needs and symp-
toms. Generally speaking, ‘high-frequency, low-impact’
exercise can be recommended. Further prospective studies
are warranted to fine-tune the training parameters, duration,
frequency, and ways to achieve an optimal and long-lasting
effect.
4.6. Safety and other considerations
Emerging evidence suggests that in a disease with severe
functional impairment, exercise training may serve as a safe,
feasible, and beneficial adjunct therapy [3,5,23,52]. The sug-
gested indications for initiating physical training in sarcoido-
sis are broad, but due to the heterogeneity of
manifestations and symptomatology, the management of
sarcoidosis patients is complex and indications as well as
relative contraindications should be taken carefully into
account. Moreover, the impact of disease severity on the
response to exercise training in sarcoidosis is still unclear.
Multifactorial sarcoidosis-related pulmonary hypertension is
a serious concern in severe sarcoidosis; however, current
international guidelines by the American Thoracic Society
and the European Respiratory Society support exercise train-
ing within the context of PR for pulmonary arterial hyper-
tension (PAH) [76]. The recommended forms of exercise
include light or moderate aerobic and light resistive training
in patients with stable disease [3,19,52]. The recommenda-
tions endorsed by the experts indicate that supervision in
these cases is beneficial (Table 5).
Future studies need to include larger and more homoge-
neous samples in terms of sarcoidosis phenotypes, disease
severity and duration, age, nutritional status, comorbidities,
and treatments. This may help reveal possible variations in
fatigue, muscle function, and exercise capacity while drawing
attention to the most severely affected phenotypes.
5. Conclusion
Sarcoidosis has many faces and many phenotypes as well as a
wide spectrum of symptoms. This justifies the fact that the
treatment strategies should be tailored to the specific needs of
the individual sarcoidosis patient, including use of training
modalities. Emerging evidence suggests that sarcoidosis
involves adverse alterations of respiratory and peripheral ske-
letal muscle morphology and function. These alterations are
clinically relevant and appear to be associated with functional
limitations, dyspnea, and fatigue. Ultimately, muscle dysfunc-
tion is a useful indication for therapeutic intervention, as it
seems partially reversible by exercise training. Observational
studies have shown that sarcoidosis patients benefit from
physical training by improving their exercise capacity as well
as reducing sarcoidosis-associated fatigue and dyspnea. An
exercise-based rehabilitation program should be offered to
all sarcoidosis patients suffering from fatigue, dyspnea, and/
or exercise intolerance. Expected outcomes are improvements
in muscle strength and endurance, reduction in fatigue, and
ultimately improvement in QoL. A thorough patient assess-
ment should be performed at the beginning and end of
rehabilitation to evaluate program outcomes, including assess-
ment of fatigue, muscle strength, and exercise capacity.
Addressing these issues in the management of sarcoidosis
patients enables clinicians to tailor their therapies. Even
more importantly, it helps the patients in their struggle with
this devastating disease and to gain more understanding. The
present study developed practical recommendations for the
use of physical training, based on available data and expert
consensus. This review provides further justification to prior-
itize the promotion of regular physical activity as part of a
comprehensive management strategy of symptomatic sarcoi-
dosis patients to reduce physical inactivity and fatigue.
However, further randomized controlled trials are needed to
consolidate these findings into specific recommendations for
including physical training and exercise rehabilitation in the
comprehensive care of patients with sarcoidosis.
6. Expert commentary
The indications for physical training and rehabilitation in sar-
coidosis are broad, but still have to be defined. So far, no
studies have evaluated this extensively. The unique clinical
picture and underlying pathophysiology of sarcoidosis may
require sarcoidosis-specific exercise prescription.
Furthermore, organ-specific manifestations, such as joint pain
and stiffness, may require modification of the standard PR
program [2], including reduction of weight-bearing exer-
cise [52].
The heterogeneity of patients with sarcoidosis, represent-
ing different phenotypes who may or may not have lung
parenchymal involvement, pain, fatigue, and/or muscle
impairment, may require modification and program adjust-
ment of the standard physical training format. The intensity
of the training should be personalized, tailored to the indivi-
dual – which might also include adjustments for daily fluctua-
tions in energy levels – to avoid aggravating the impairments,
which would result in high dropout rates [2]. Besides, as with
other chronic cardiopulmonary diseases, exercise limitation in
sarcoidosis is most likely to be multifactorial, meaning that
exercise capacity is not limited by any single component of
the disease process, but rather by their collective quantitative
interaction(s). This reinforces the need for clinicians to tailor all
components of the rehabilitation program to the specific
needs of people with sarcoidosis. Despite the limited studies,
the initial results are promising, providing sufficient justifica-
tion for further investigation with multicenter randomized
trials. Challenges for future research include patient selection,
along with the specific components of physical training to
optimize the benefits. The consensus results presented here
are a first attempt to produce recommendations for the use of
physical training for various manifestations of sarcoidosis. In
view of the paucity of data, an optimal training program
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(types of exercises, intensities, frequency, and duration) still
needs to be defined to optimize training adjustments, espe-
cially regarding the reduction of fatigue. Again, characteriza-
tion of disease phenotypes may provide the guidance that is
necessary for a structured tailored physical training and life-
style intervention program, with an emphasis on determinants
of modifiable lifestyle habits [77]. Moreover, psychological
aspects and coping with the disease should be covered as
well. Prospective studies should be designed to answer linger-
ing questions about the value of exercise training for patients
with sarcoidosis, including finding the optimal type and
dosage of exercise, the benefits that can be expected from
maintenance programs, and how long these benefits will last.
The accumulated knowledge about the importance of physical
training in symptomatic sarcoidosis patients is promising
enough for it to be implemented.
7. Five-year view
Sarcoidosis patients generally benefit from additional non-
pharmacologic treatments, not only physical training but
also nutritional supplements and counseling [56,78].
Therefore, patients should be aware of their opportunities
for managing their own condition, including ways to engage
different services when required, and lifestyle, for example, the
importance of regular exercise as well as physical training
programs. Patients’ knowledge about the importance of exer-
cise for their health (in addition to drug therapy) should be
improved [10].
A growing body of evidence has demonstrated the exer-
cise-limiting effects of sarcoidosis, suggesting that, in general,
patients with sarcoidosis may indeed benefit from an exercise
program. However, evidenced-based guidelines have to be
established. A thorough patient assessment at entry into reha-
bilitation will assist in tailoring the exercise program to their
individual needs. Health education, using self-administered
modules and continued supervised home practice of physical
training for chronic symptomatic sarcoidosis-associated fati-
gue, will add significant and sustained benefits to conven-
tional therapy while reducing costs [79].
The phenomenon of muscle dysfunction in sarcoidosis
demands a wider appreciation and deeper understanding.
The pathogenesis, molecular basis, and extent of muscle
dysfunction should be further explored. Larger, robustly
designed studies can help establish whether both respira-
tory and limb muscles are affected. Whether the demon-
strated muscle defects represent the consequences of
systemic abnormalities stemming from the primary patho-
biology and multisystemic character of sarcoidosis, or con-
stitute manifestations of a primary myopathic process,
remains to be explored. The role of inflammation, oxidative
stress, physical inactivity and the possible effect of sarcoi-
dosis-specific therapy are likely to be better characterized.
Finally, studies exploring sarcoidosis-specific treatment influ-
ences on aspects of skeletal muscle function, morphology,
and enzyme activities should provide the required insights.
Ultimately, all aspects of muscle alterations in sarcoidosis
should be considered and interpreted within the context of
disease heterogeneity, duration, and severity, with disease
phenotypes identified and physical training targeted appro-
priately to these differing needs.
Studies in IPF and Parkinson’s disease have reported
increased awareness of the benefits of home-based physical
training, supervised by physical therapists online and/or by
phone calls, in terms of reduction of burden of disease
(muscle strength, exercise capacity, fatigue, mental status,
and QoL), and the same benefits may be achieved in
patients with sarcoidosis [6,79,80]. These findings could
guide a feasibility study outlining ‘best practice’ in other
chronic disorders, in which home-based supervised physical
training programs are expected to improve QoL and reduce
the burden of disease. The results can be used to stimulate
broader initiatives to promote supervised physical training in
sarcoidosis as well as other ILDs, and help develop national
and international guidelines. Just as in many other chronic
diseases, it is now time for the health-care systems to create
the necessary infrastructure to ensure that supervised exer-
cise can be prescribed as treatment. Moreover, it is impor-
tant that society in general supports a physically active
lifestyle. People do not exercise when you just tell them
to; people start to exercise when the context compels
them to do so. In order to enhance the physical activity
level of a population, accessibility is important. There is a
need for political statements and regulations about ‘health
consequences’. Politicians should also consider health
aspects, including how infrastructure and architecture may
influence the population’s physical activity levels.
Key issues
● Sarcoidosis is a systemic heterogenic disease affecting the
lungs in most cases. The evolution (progression, improve-
ment, or stability) and impact of sarcoidosis are variable.
● Sarcoidosis patients often present with non-specific symp-
toms, such as reduced exercise capacity, peripheral and
respiratory muscle strength impairment, and dyspnea. The
hallmark and most frustrating symptom of sarcoidosis is
fatigue.
● International sarcoidosis experts suggest considering physi-
cal training in patients suffering from sarcoidosis-associated
fatigue. Important indications for initiating physical training
by fatigued sarcoidosis patients were considered to be the
presence of pulmonary, muscular, as well as other extra-
pulmonary involvement.
● The heterogeneity of patients with sarcoidosis will require
modification and program adjustments to the standard
rehabilitation format for e.g. COPD, ILD or other chronic
diseases.
● In view of the paucity of data, an optimal training program
(types of exercises, intensities, frequency, duration) still
needs to be defined in order to optimize training specifica-
tions, especially with the aim reducing fatigue.
● A thorough characterization of the sarcoidosis phenotypes
in terms of manifestations and limitations is necessary to
find determinants of physical activities that are modifiable
by changing lifestyle habits and to develop structured tai-
lored exercise training and lifestyle interventions.
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● Randomized controlled trials are needed to consolidate the
limited data into specific recommendations for physical
training in patients with sarcoidosis.
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